Chowdhury S, Xiu J, Ribeiro JR, Nicolaides T, et al. Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors. Br J Cancer 2024 Sep 4. doi: 10.1038/s41416-024-02826.
PMID: 39227409